Tech Company Financing Transactions
Solstice Neurosciences Funding Round
On 11/8/2006, Solstice Neurosciences raised $85 million in Series B funding from Highland Capital Partners, Investor Growth Capital and Morgan Stanley Expansion Capital.
Transaction Overview
Company Name
Announced On
11/8/2006
Transaction Type
Debt
Venture Equity
Venture Equity
Amount
$85,000,000
Round
Series B
Investors
Proceeds Purpose
These new funds will support the company's ongoing initiatives related
to movement disorders and treatment for cervical dystonia using Myobloc(R)
(Botulinum Toxin Type B) Injectable Solution (also sold and distributed as
NeuroBloc(R) in Europe).
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
701 Gateway Boulevard 250
South San Francisco, CA 94080
USA
South San Francisco, CA 94080
USA
Phone
Website
Email Address
Overview
Solstice Neurosciences, Inc. is a biopharmaceuticalcompany focused on the development, manufacturing, sales and marketing ofspecialty products.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Dennis Smith
Chief Financial Officer
Michael Pagnotta
VP - Operations
Patrick Murphy
Browse more venture capital transactions:
Prev: 11/8/2006: AlterPoint venture capital transaction
Next: 11/9/2006: BlackArrow venture capital transaction
Share this article
Where The Data Comes From
We report on funding rounds that are announced publicly. All VC database entries reported here are sourced from publicly available VC deal announcements. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs